Gallbladder Cancer - Pipeline Review, H2 2017

  • ID: 4433859
  • Report
  • 179 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • Eli Lilly and Co
  • Hutchison MediPharma Ltd
  • Kringle Pharma Inc
  • MedImmune LLC
  • MORE
Gallbladder Cancer - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • Eli Lilly and Co
  • Hutchison MediPharma Ltd
  • Kringle Pharma Inc
  • MedImmune LLC
  • MORE
Introduction

Gallbladder Cancer - Overview

Gallbladder Cancer - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gallbladder Cancer - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gallbladder Cancer - Companies Involved in Therapeutics Development

4SC AG

Advenchen Laboratories LLC

Array BioPharma Inc

Aslan Pharmaceuticals Pte Ltd

Bayer AG

BeiGene Ltd

Eli Lilly and Co

Halozyme Therapeutics Inc

Hutchison MediPharma Ltd

Ipsen SA

Kringle Pharma Inc

Leap Therapeutics Inc

MedImmune LLC

Molecular Templates Inc

Novartis AG

NuCana Plc

OncoTherapy Science Inc

VasGene Therapeutics Inc

Gallbladder Cancer - Drug Profiles

apatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGBA-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

binimetinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

copanlisib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DKN-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

evofosfamide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

merestinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUC-1031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCVC-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEGPH-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ramucirumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resminostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trametinib dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varlitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vas-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gallbladder Cancer - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gallbladder Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Gallbladder Cancer - Pipeline by 4SC AG, H2 2017

Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017

Gallbladder Cancer - Pipeline by Array BioPharma Inc, H2 2017

Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017

Gallbladder Cancer - Pipeline by Bayer AG, H2 2017

Gallbladder Cancer - Pipeline by BeiGene Ltd, H2 2017

Gallbladder Cancer - Pipeline by Eli Lilly and Co, H2 2017

Gallbladder Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017

Gallbladder Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017

Gallbladder Cancer - Pipeline by Ipsen SA, H2 2017

Gallbladder Cancer - Pipeline by Kringle Pharma Inc, H2 2017

Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H2 2017

Gallbladder Cancer - Pipeline by MedImmune LLC, H2 2017

Gallbladder Cancer - Pipeline by Molecular Templates Inc, H2 2017

Gallbladder Cancer - Pipeline by Novartis AG, H2 2017

Gallbladder Cancer - Pipeline by NuCana Plc, H2 2017

Gallbladder Cancer - Pipeline by OncoTherapy Science Inc, H2 2017

Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H2 2017

Gallbladder Cancer - Dormant Projects, H2 2017

List of Figures

Number of Products under Development for Gallbladder Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • Advenchen Laboratories LLC
  • Array BioPharma Inc
  • Aslan Pharmaceuticals Pte Ltd
  • Bayer AG
  • BeiGene Ltd
  • Eli Lilly and Co
  • Halozyme Therapeutics Inc
  • Hutchison MediPharma Ltd
  • Ipsen SA
  • Kringle Pharma Inc
  • Leap Therapeutics Inc
  • MedImmune LLC
  • Molecular Templates Inc
  • Novartis AG
  • NuCana Plc
  • OncoTherapy Science Inc
  • VasGene Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll